RBC Starts Cepheid (CPHD) at Outperform
More News related to CPHD
- Cepheid (CPHD) Noted New England's Journal of Medicine Study Highlights Need for Rapid, PCR-based Group B Streptococcus (GBS) Testing at Time of Admission for Labor and Delivery
- New England Journal of Medicine Study Highlights Need for Rapid, PCR-based Group B Streptococcus (GBS) Testing at Time of Admission for Labor and Delivery
- Cepheid (CPHD) Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia
- Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)
- Cepheid (CPHD) Wins Grant to Develop Ten-Color Real-Time PCR Detection Technology for GeneXpert(R) System
RBC Capital initiates coverage on Cepheid (Nasdaq: CPHD) with an Outperform rating.
Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for genetic testing in the clinical molecular diagnostic, industrial, and biothreat markets.
Related Categories
New CoverageStocks Mentioned
-0.27Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
